TNF and cancer: MEFs treated by TGFß1 were enriched in terms associated with TGFß1 signaling (i.e., R-MMU-445144: signal transduction by L1) and ECM-modeling (i.e., mmu05205: proteoglycan in cancer), while MEFs treated by TNFα were enriched in pathways related to acute phase response (i.e., GO:0042743: hydrogen peroxide metabolic process) (See Fig. 2d–e; Supplementary Table S2).